Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 17/20 | 0.76 |
| ▸ | HDAC1 | Q13547 | 13/20 | 0.76 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.76 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.74 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.74 |
| ▸ | NAAA | Q02083 | 1/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6640133 | 0.98 | HDAC3 (0.77) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL6636519 | 0.95 | HDAC3 (0.82) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL17141819 | 0.91 | HDAC3 (0.91) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL8423787 | 0.87 | HDAC3 (0.79) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL21435718 | 0.87 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL21435742 | 0.86 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC8NAAA | |
| SCHEMBL21435717 | 0.86 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC8NAAA | |
| SCHEMBL21435734 | 0.86 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC8NAAA | |
| SCHEMBL21435731 | 0.86 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC8NAAA | |
| SCHEMBL28970457 | 0.86 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC8NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116535357-A | Arylamino benzamide derivative containing substituted pyrazole structure, preparation method and application | 西北农林科技大学 | 2023-08-04 | — | — | CN | claimed |
| CN-116535357-A | Arylamino benzamide derivative containing substituted pyrazole structure, preparation method and application | 西北农林科技大学 | 2023-08-04 | — | — | CN | disclosed |
| CN-116535357-A | Arylamino benzamide derivative containing substituted pyrazole structure, preparation method and application | 西北农林科技大学 | 2023-08-04 | — | — | CN | disclosed |
| CN-116535357-A | Arylamino benzamide derivative containing substituted pyrazole structure, preparation method and application | 西北农林科技大学 | 2023-08-04 | — | — | CN | disclosed |
| US-20110065734-A1 | NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES | 4SC AG (DE) | 2011-03-17 | — | — | US | disclosed |
| EP-2060565-A1 | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases | 4SC AG (DE) | 2009-05-20 | — | — | EP | disclosed |
| US-5955506-A | ACETAMIDOBENZAMIDE COMPOUNDS FOR TREATMENT OF PARKINSON'S DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065734-A1 | NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES | HDAC1, HDAC11, MAP2K2 | HDAC3 18/4885HDAC1 1/4885HDAC2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.